Services & Niche

Natera, Inc. (NASDAQ: NTRA) is a pioneering genetic testing company leveraging its expertise in cell-free DNA (cfDNA) to advance oncology care, with a sharp focus on Molecular Residual Disease (MRD) detection. Its flagship service in this space is Signatera, a personalized circulating tumor DNA (ctDNA) test designed to identify minute traces of tumor DNA remaining in the body after treatment.

Unlike conventional fixed-panel liquid biopsy tests, Signatera creates a customized assay tailored to each patient’s tumor genomics. This tumor-informed approach allows for highly sensitive and specific monitoring of residual disease and early detection of recurrence—often months before conventional imaging can identify relapse. Natera’s Signatera is currently used across various cancer types, including colorectal, breast, lung, and bladder cancer, where early intervention can make a critical difference in patient outcomes.

In addition to recurrence monitoring, Signatera’s applications are expanding to include therapy response monitoring (tracking tumor burden over time) and detection of immunotherapy-related biomarkers, providing a non-invasive, blood-based alternative to repeated imaging and invasive biopsies.

Proof of Concept & Validation

Signatera’s clinical utility is backed by robust evidence from multiple studies across solid tumors:

In the landmark CIRCULATE-Japan study (GALAXY arm) involving 2,240 colorectal cancer patients, post-surgical ctDNA status was found to be highly prognostic. Patients who tested Signatera-positive after curative surgery had nearly a 10-fold worse three-year overall survival compared to ctDNA-negative patients.
The data, presented at ESMO 2024 and published in Nature Medicine, demonstrated that MRD detection predicts long-term survival and can guide adjuvant therapy decisions. Signatera-positive patients benefited significantly from chemotherapy, with a 50% reduction in the risk of death when treated with adjuvant chemotherapy.
Additional studies in lung and breast cancers have shown Signatera’s ability to detect recurrence 6–12 months earlier than radiological scans, with sensitivity rates of 85–90% and minimal false positives.

Though currently offered as an LDT (Laboratory Developed Test), these validations have supported clinical adoption and inclusion in clinical trial protocols and guidelines. Signatera has also secured Medicare coverage for select indications, including stage II-III colorectal cancer MRD surveillance, reflecting its clinical relevance and real-world utility ahead of FDA approval.

Revenue & Market Position

Natera’s diversified business spans women’s health (non-invasive prenatal testing), organ transplant diagnostics, and oncology. While oncology is the newest vertical, it is also the fastest-growing segment, increasingly contributing to Natera’s revenue and testing volumes.

2024 Milestones:

Total revenue reached $1.697 billion, marking a 56.7% increase year-over-year.
Natera processed approximately 528,200 oncology tests, up 54.9% from 2023, indicating robust Signatera adoption.

While prenatal testing remains the largest revenue contributor, oncology is now the core growth driver, positioning Natera as a first-mover in the MRD market. The company is effectively creating a new category of personalized MRD-based cancer management, targeting patients post-surgery or in remission across solid tumor types.

With an addressable market that includes:

~150,000 stage II-III colorectal cancer patients in the US (for guiding adjuvant chemotherapy decisions)
Equally large pools in breast and lung cancer,

Natera’s early leadership and evidence-based approach have afforded it a competitive edge. While academic institutions and startups are entering the space, no other FDA-approved MRD tests for solid tumors currently exist, granting Natera a first-mover advantage.

Technology & Differentiation

At the core of Signatera’s success is its ultra-deep next-generation sequencing (NGS) technology and patient-specific design:

For each patient, Natera sequences the tumor to identify 16+ unique mutations.
A personalized multiplex PCR assay is developed to quantitatively track these mutations in the patient’s blood over time.

This approach provides:

Exceptional sensitivity (detecting a single mutant molecule amid 10^5–10^6 normal DNA fragments)
Minimized false positives, avoiding confusion from non-tumor mutations (e.g., clonal hematopoiesis).

Although Signatera’s process requires access to tumor tissue and more upfront customization, Natera has automated and scaled these processes efficiently, leveraging its high-throughput commercial lab expertise from the prenatal business.

Key differentiators:

Proprietary MRD methodology supported by a broad IP portfolio
Smart bioinformatics filters to exclude confounding signals
A highly scalable and automated lab infrastructure

These advantages make Signatera uniquely positioned in the liquid biopsy market, offering precision and reliability that generic fixed-panel ctDNA tests cannot match.

Case Studies & Industry Examples

Case Study 1: CIRCULATE-Japan (GALAXY Arm)

Scope: 2,240 colorectal cancer patients
Outcome: Post-operative Signatera-positive status predicted 10x worse survival.
Impact: Informed adjuvant chemo decisions, reducing mortality risk by 50% for Signatera-positive patients receiving treatment.

Case Study 2: Natera’s Collaboration with NSCLC Trials

Scope: MRD detection in non-small cell lung cancer (NSCLC) trials
Outcome: Signatera detected recurrence 6 months ahead of scans.
Impact: Early identification of relapse allowed earlier intervention, potentially improving outcomes in early-stage NSCLC.

Case Study 3: Breast Cancer MRD Monitoring

Scope: Post-surgical and adjuvant treatment breast cancer patients
Outcome: 85–90% sensitivity for early recurrence detection, up to 12 months earlier than imaging.
Impact: Personalized treatment de-escalation, avoiding unnecessary chemotherapy for MRD-negative patients.

Conclusion & Call to Action

Key Takeaways:

Signatera offers personalized MRD testing that enhances recurrence monitoring and treatment decision-making.
Natera’s first-mover advantage and clinical validation position it as the leader in MRD testing for solid tumors.
Oncology is the company’s fastest-growing segment, with strong revenue growth and market expansion potential.

Future Perspectives:

Broader technology adoption as MRD testing becomes a standard of care.
Regulatory milestones, including FDA approval, will solidify payer coverage and clinical integration.
Emerging market trends suggest significant uptake in pharma trials and routine monitoring for solid tumors, creating a multi-billion-dollar opportunity.

Recommendations:

Oncology professionals and health systems should consider integrating Signatera into standard post-treatment surveillance.
Pharma partners can leverage Natera’s MRD platform for trial enrichment, response monitoring, and adaptive trial designs.
Investors may find compelling growth prospects in Natera’s expansion into oncology, reinforcing its role in precision medicine.

👉 Stay informed on Natera’s latest developments in MRD testing and precision oncology.
Subscribe to our newsletter or contact us to explore collaboration opportunities.

Resources & References

CIRCULATE-Japan Study (GALAXY Arm)
Presented at ESMO 2024; published in Nature Medicine
➡️ Nature Medicine Publication
➡️ CIRCULATE-Japan Overview on ESMO
Natera Official Website – Signatera Clinical Data
➡️ Signatera Product Page
➡️ Clinical Evidence for Signatera
Biospace – Natera Industry Coverage
➡️ Natera’s Personalized MRD Testing Overview on BioSpace
Medicare Coverage – MRD Surveillance in Colorectal Cancer
➡️ CMS Local Coverage Determination (LCD) for Signatera in Colorectal Cancer
ESMO 2024 Congress Proceedings (Natera Presentations)
➡️ ESMO Congress 2024 Abstract Book
(Search for "Natera" or "Signatera" in the abstract book for specific sessions)
NSCLC Clinical Trial Data (Journal of Clinical Oncology)
➡️ Journal of Clinical Oncology – MRD in NSCLC
(You may need institutional access or purchase for full text.)
Oncology Times – Expert Commentary on MRD and Liquid Biopsy
➡️ Oncology Times: Liquid Biopsy and MRD
(Search for "MRD" or "Natera" for recent expert articles.)
FDA Guidance on Liquid Biopsy and MRD Assays
➡️ FDA Guidance for Industry: Considerations for ctDNA-Based MRD Assays
Natera 2024 Annual Report – Financials and Oncology Strategy
➡️ Natera Investor Relations – Annual Reports
➡️ Natera Q4 2024 Earnings Call Transcript

APB

Liquid Biopsy Compny, Natera: Personalized MRD Testing for Recurrence Monitoring